User login
Key clinical point: The combination of S-1 and oxaliplatin (SOX) with bevacizumab (B-mab) or cetuximab (C-mab) had almost similar efficacy and safety as first-line chemotherapy for previously untreated recurrent advanced colorectal cancer (CRC) with wild-type KRAS.
Major finding: The overall response rates in the SOX+B-mab and SOX+C-mab arms were 59.1% and 43.5% (P = .29) and disease control rates were 90.9% and 91.3% (P = .96), respectively. The median overall survival (25.3 months vs 15.5 months; P = .167) and median progression-free survival (11.7 months vs 5.5 months; P = .077) were similar for SOX+B-mab and SOX+C-mab groups. Grade 3 or more adverse events were reported by 45.6% and 47.8% of patients in the SOX+B-mab and SOX+C-mab groups, respectively.
Study details: This was a randomized, phase 2 trial including 45 patients with previously untreated, locally advanced, or metastatic CRC with wild-type KRAS randomly assigned to SOX+B-mab or SOX+C-mab.
Disclosures: The study did not receive any specific grant from funding agencies. The authors declared no conflict of interests.
Source: Nishizawa Y et al. BMC Cancer. 2021 Aug 23. doi: 10.1186/s12885-021-08690-y.
Key clinical point: The combination of S-1 and oxaliplatin (SOX) with bevacizumab (B-mab) or cetuximab (C-mab) had almost similar efficacy and safety as first-line chemotherapy for previously untreated recurrent advanced colorectal cancer (CRC) with wild-type KRAS.
Major finding: The overall response rates in the SOX+B-mab and SOX+C-mab arms were 59.1% and 43.5% (P = .29) and disease control rates were 90.9% and 91.3% (P = .96), respectively. The median overall survival (25.3 months vs 15.5 months; P = .167) and median progression-free survival (11.7 months vs 5.5 months; P = .077) were similar for SOX+B-mab and SOX+C-mab groups. Grade 3 or more adverse events were reported by 45.6% and 47.8% of patients in the SOX+B-mab and SOX+C-mab groups, respectively.
Study details: This was a randomized, phase 2 trial including 45 patients with previously untreated, locally advanced, or metastatic CRC with wild-type KRAS randomly assigned to SOX+B-mab or SOX+C-mab.
Disclosures: The study did not receive any specific grant from funding agencies. The authors declared no conflict of interests.
Source: Nishizawa Y et al. BMC Cancer. 2021 Aug 23. doi: 10.1186/s12885-021-08690-y.
Key clinical point: The combination of S-1 and oxaliplatin (SOX) with bevacizumab (B-mab) or cetuximab (C-mab) had almost similar efficacy and safety as first-line chemotherapy for previously untreated recurrent advanced colorectal cancer (CRC) with wild-type KRAS.
Major finding: The overall response rates in the SOX+B-mab and SOX+C-mab arms were 59.1% and 43.5% (P = .29) and disease control rates were 90.9% and 91.3% (P = .96), respectively. The median overall survival (25.3 months vs 15.5 months; P = .167) and median progression-free survival (11.7 months vs 5.5 months; P = .077) were similar for SOX+B-mab and SOX+C-mab groups. Grade 3 or more adverse events were reported by 45.6% and 47.8% of patients in the SOX+B-mab and SOX+C-mab groups, respectively.
Study details: This was a randomized, phase 2 trial including 45 patients with previously untreated, locally advanced, or metastatic CRC with wild-type KRAS randomly assigned to SOX+B-mab or SOX+C-mab.
Disclosures: The study did not receive any specific grant from funding agencies. The authors declared no conflict of interests.
Source: Nishizawa Y et al. BMC Cancer. 2021 Aug 23. doi: 10.1186/s12885-021-08690-y.